The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective coronary artery bypass grafting (CABG) surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentrations and on postoperative markers of myocardial and kidney injury.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
1. Age ≥18 years
2. Scheduled to undergo elective isolated CABG surgery with cardiopulmonary bypass (CPB)
3. At increased risk of postoperative complications based on ≥1 of the following:
1. Age ≥65 years
2. eGFR \<45 ml/min/1.73m2
3. Documented history of congestive h…
Inclusion Criteria:
1. Age ≥18 years
2. Scheduled to undergo elective isolated CABG surgery with cardiopulmonary bypass (CPB)
3. At increased risk of postoperative complications based on ≥1 of the following:
1. Age ≥65 years
2. eGFR \<45 ml/min/1.73m2
3. Documented history of congestive heart failure or left ventricular ejection fraction (LVEF) ≤40% within 6 months before surgery
4. Diabetes mellitus and urine albumin-to-creatinine ratio \>30 mg/g creatinine
5. Peripheral arterial disease
6. Anemia, defined as hemoglobin \<10 g/dl
7. Prior cardiac surgery
Exclusion Criteria:
1. Any of the following laboratory abnormalities at the time of screening:
1. ALT \>3-fold the upper limit of normal
2. eGFR \<30 ml/min/1.73m2 or ESKD on dialysis
3. Hemoglobin \<8 g/dl
2. History of gastric bypass or malabsorption
3. Active alcohol or illicit substance use in the prior 6 months
4. Participation in an investigational trial to evaluate pharmaceuticals or biologics within the past 3 months or 5 half-lives, whichever is shorter
5. Pregnant or breast-feeding
6. Unwillingness to use contraception while taking study drug and for 8 weeks after the last dose for women of reproductive age or non-sterilized male participants who are sexually active with a female partner of childbearing potential
7. Current use of niacin \>100 mg/day or NMN, nicotinamide, or nicotinamide riboside at any dose
8. Conflict with other research studies
9. Any condition which, in the judgement of the investigator, might increase the risk to the participant
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.